Sopharma Trading AD (BUL: SFT)
Bulgaria
· Delayed Price · Currency is BGN
5.80
-0.05 (-0.85%)
At close: Dec 23, 2024
Sopharma Trading AD Income Statement
Financials in millions BGN. Fiscal year is January - December.
Millions BGN. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
Operating Revenue | 1,848 | 1,673 | 1,479 | 1,336 | 1,156 | 945.81 | Upgrade
|
Other Revenue | 8.16 | 5.05 | 4.26 | - | - | - | Upgrade
|
Revenue | 1,857 | 1,678 | 1,483 | 1,336 | 1,156 | 945.81 | Upgrade
|
Revenue Growth (YoY) | 14.65% | 13.20% | 11.00% | 15.53% | 22.25% | 6.53% | Upgrade
|
Cost of Revenue | 1,626 | 1,482 | 1,311 | 1,193 | 1,052 | 865.21 | Upgrade
|
Gross Profit | 230.14 | 196.02 | 172.13 | 142.34 | 104.06 | 80.59 | Upgrade
|
Selling, General & Admin | 138.75 | 115.65 | 100.73 | 97.75 | 71.81 | 62.72 | Upgrade
|
Other Operating Expenses | 3.28 | 3.59 | 1.47 | -0.29 | -5.3 | -9.23 | Upgrade
|
Operating Expenses | 176.78 | 151.35 | 132.26 | 126.29 | 86.67 | 69.03 | Upgrade
|
Operating Income | 53.36 | 44.68 | 39.87 | 16.05 | 17.39 | 11.57 | Upgrade
|
Interest Expense | -9.56 | -8.42 | -5.18 | -5.36 | -4.46 | -4 | Upgrade
|
Interest & Investment Income | 1.01 | 0.46 | 0.71 | 2.11 | 1.67 | 2.93 | Upgrade
|
Earnings From Equity Investments | -0.07 | - | - | - | - | - | Upgrade
|
Currency Exchange Gain (Loss) | -1.95 | -0.13 | -0.11 | -0.16 | -0.19 | 0.11 | Upgrade
|
Other Non Operating Income (Expenses) | -2.08 | -2.63 | -1.75 | -0.97 | -0.84 | -0.51 | Upgrade
|
EBT Excluding Unusual Items | 40.71 | 33.96 | 33.55 | 11.66 | 13.57 | 10.1 | Upgrade
|
Impairment of Goodwill | - | - | -13.33 | - | - | - | Upgrade
|
Gain (Loss) on Sale of Assets | 0.55 | 0.21 | 0.46 | 0.3 | 0.25 | 0.11 | Upgrade
|
Asset Writedown | - | - | -8.28 | -2.64 | - | -0.02 | Upgrade
|
Other Unusual Items | 0 | - | - | 0.12 | 0.1 | - | Upgrade
|
Pretax Income | 41.26 | 34.18 | 12.39 | 9.44 | 13.92 | 10.18 | Upgrade
|
Income Tax Expense | 3.55 | 4.15 | 3.31 | 1.39 | 2.45 | 1.38 | Upgrade
|
Earnings From Continuing Operations | 37.71 | 30.03 | 9.08 | 8.05 | 11.48 | 8.8 | Upgrade
|
Minority Interest in Earnings | 0.43 | - | - | - | - | 0.12 | Upgrade
|
Net Income | 38.15 | 30.03 | 9.08 | 8.05 | 11.48 | 8.92 | Upgrade
|
Net Income to Common | 38.15 | 30.03 | 9.08 | 8.05 | 11.48 | 8.92 | Upgrade
|
Net Income Growth | 308.97% | 230.70% | 12.80% | -29.85% | 28.60% | 2.37% | Upgrade
|
Shares Outstanding (Basic) | 34 | 34 | 34 | 34 | 34 | 34 | Upgrade
|
Shares Outstanding (Diluted) | 34 | 34 | 34 | 34 | 34 | 34 | Upgrade
|
Shares Change (YoY) | 0.66% | - | - | - | - | 4.17% | Upgrade
|
EPS (Basic) | 1.11 | 0.88 | 0.26 | 0.23 | 0.33 | 0.26 | Upgrade
|
EPS (Diluted) | 1.11 | 0.88 | 0.26 | 0.23 | 0.33 | 0.26 | Upgrade
|
EPS Growth | 306.28% | 230.70% | 12.80% | -29.85% | 28.60% | -1.72% | Upgrade
|
Free Cash Flow | 46.14 | 37.63 | 12.84 | -180.39 | -225.62 | -198.94 | Upgrade
|
Free Cash Flow Per Share | 1.34 | 1.10 | 0.37 | -5.26 | -6.58 | -5.80 | Upgrade
|
Gross Margin | 12.40% | 11.68% | 11.61% | 10.66% | 9.00% | 8.52% | Upgrade
|
Operating Margin | 2.87% | 2.66% | 2.69% | 1.20% | 1.50% | 1.22% | Upgrade
|
Profit Margin | 2.05% | 1.79% | 0.61% | 0.60% | 0.99% | 0.94% | Upgrade
|
Free Cash Flow Margin | 2.49% | 2.24% | 0.87% | -13.50% | -19.51% | -21.03% | Upgrade
|
EBITDA | 82.09 | 73.5 | 67.21 | 28.08 | 26.02 | 18.6 | Upgrade
|
EBITDA Margin | 4.42% | 4.38% | 4.53% | 2.10% | 2.25% | 1.97% | Upgrade
|
D&A For EBITDA | 28.72 | 28.82 | 27.34 | 12.03 | 8.63 | 7.03 | Upgrade
|
EBIT | 53.36 | 44.68 | 39.87 | 16.05 | 17.39 | 11.57 | Upgrade
|
EBIT Margin | 2.87% | 2.66% | 2.69% | 1.20% | 1.50% | 1.22% | Upgrade
|
Effective Tax Rate | 8.60% | 12.13% | 26.73% | 14.70% | 17.57% | 13.58% | Upgrade
|
Advertising Expenses | - | 6.55 | 4.14 | 3.46 | 3.12 | 4.66 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.